Eli Lilly is suing pharmacies and peptide vendors over sale of its next big weight-loss drug: retatrutide

Eli Lilly is taking legal action against pharmacies and vendors selling compounded versions of its upcoming weight-loss drug, retatrutide, to Americans seeking quick access to the medication. Compounded versions of drugs are not FDA-approved and can pose health risks, prompting Lilly's lawsuit. This move underscores the growing trend of individuals bypassing traditional healthcare channels for unapproved treatments, highlighting the broader issue of drug regulation and patient safety. Lilly's actions could set a precedent for how pharmaceutical companies handle the sale of new medications.